However, in a phase II trial (NCT01954745) treating patients with advanced CCA, the unselective tyrosine kinase and MET inhibitor cabozantinib demonstrated no significant anti-tumor activity in an unselected patient population [206]. This evidence concerns the gene MET and cholangiocarcinoma.